Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. Poster 2 details the Phase 2b randomized, double-blinded study ...

BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that the company will be presenting 16 posters and exhibiting ...